Disclaimer

VDX-10 is patent-pending (Provisional Patent Application No. 64/082,295, filed June 4, 2026; non-provisional deadline June 2027). LyticGen Pharmaceuticals, Inc. is a development-stage biopharmaceutical company. VDX-10 has not received FDA approval or clearance, has not completed clinical trials, and is not commercially available. Statements on this website regarding VDX-10’s therapeutic potential, performance characteristics, and development timeline are based on management’s current assumptions and analysis of peer-reviewed scientific literature on comparable CRISPR-enhanced and natural bacteriophage systems. No independent GLP-standard testing or clinical validation of VDX-10 production lots has been completed to date. Actual performance may differ materially depending on formulation, manufacturing process, bacterial strain variation, host immune environment, and experimental conditions. Independent preclinical testing is required before any estimated properties may be relied upon for regulatory submissions, clinical trial planning, licensing negotiations, or commercial decisions.  Market data and projections referenced on this website are sourced from third-party research firms and are provided for general informational context only. They do not imply that LyticGen Pharmaceuticals or VDX-10 will capture any specific share of any market. All forward-looking statements involve risks and uncertainties, and actual results may differ materially from those projected.  Nothing on this website constitutes an offer or solicitation to sell securities in any jurisdiction. Any securities offering is made only through appropriate offering documents and is available to accredited investors only in accordance with applicable law. All investments involve risk, including the possible loss of invested capital. Past performance is not indicative of future results.  This website does not constitute legal, tax, regulatory, or investment advice. Visitors should consult independent qualified advisors before making any investment or business decision based on information on this website.  © 2026 LyticGen Pharmaceuticals, Inc. All rights reserved.